ST. LOUIS– C2N Diagnostics, LLC, a specialty diagnostics company dedicated to advancing brain health, announced today that it will triple the size of its operations with a new headquarters in the Cortex Innovation District in Midtown St. Louis. The expansion underscores the company’s rapid growth and its leading role in developing innovative diagnostics for Alzheimer’s disease.
C2N will relocate its headquarters to 4140 Forest Park Ave. at Catalyst, Powered by WashU, a redevelopment of the former Goodwill Industries site by Washington University. The company will occupy more than 82,000 square feet across the first three floors of the facility, with the move expected to begin in late 2026. The new site will house C2N’s federally regulated, CAP-accredited and CLIA-certified lab, leveraging the latest bioautomation and high-resolution proteomic testing technologies.
In addition to its new headquarters, C2N will maintain its ISO 13485:2016 compliant facility, which will become a center dedicated to multi-omic solutions and advanced analytical platforms to support biopharmaceutical research services, medtech initiatives, and international collaborations.
“This expansion is a testament to the enthusiastic support we’ve received in St. Louis, the talented team we’ve built, and the health care professionals who have embraced our technology and high-quality testing services,” said Dr. Joel Braunstein, CEO of C2N Diagnostics. “We are especially excited to grow within the Cortex Innovation District, where we first started, and continue to be part of its mission to shape the future of health innovation.”
Missouri Governor Mike Kehoe praised the announcement, saying, “The ongoing success of C2N Diagnostics in St. Louis is proof that Missouri is leading the way in groundbreaking medical research. Their partnership with Washington University demonstrates the powerful impact of science and entrepreneurship happening here in our state.”
C2N is best known for commercializing the first clinical blood test for Alzheimer’s disease and, more recently, the PrecivityAD2™ blood test, which helps clinicians detect amyloid plaques in the brain and inform medical management and treatment decisions. To date, more than 50,000 Precivity™ analytes have been reported in peer-reviewed publications, and over 150 global collaborations are using the company’s biomarkers in research. C2N is now expanding its pipeline with assays targeting tau pathology, research into Parkinson’s disease, and new technologies to decentralize mass spectrometry testing.
The company has also announced strategic partnerships and investments in recent months, including support from Samsung C&T Corporation, Samsung Biologics, Samsung Bioepis, and Samsung Venture Investment Corporation, as well as a collaboration with The Michael J. Fox Foundation. C2N has expanded internationally with medical device registration in the United Kingdom and operations in Canada.
“When WashU acquired the former Goodwill building in the Cortex Innovation District, we saw more than a property — we saw potential,” said Doug Frantz, vice chancellor for innovation and commercialization at Washington University. “With Catalyst, that potential becomes reality. We are so pleased to welcome C2N as our anchor tenant. This is a full-circle moment, as the company was co-founded by WashU researchers with technology spun out of the university.”
“C2N’s expansion in St. Louis is yet another example of our region’s strength in neuroscience research,” added Dustin Allison, Interim CEO of Greater St. Louis, Inc. “Their growth not only advances human health but also strengthens our region’s economic development.”
C2N expressed its appreciation to state and local leaders, including Governor Mike Kehoe, St. Louis Mayor Cara Spencer, Alderman Michael Browning, the Cortex Innovation District, and other partners who supported the expansion. The company currently operates out of BioSTL and CIC facilities in the Cortex district.
